Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.

Misiewicz-Krzeminska I, Corchete LA, Rojas EA, Martínez-López J, García-Sanz R, Oriol A, Bladé J, Lahuerta JJ, Miguel JS, Mateos MV, Gutiérrez NC.

Haematologica. 2018 May;103(5):880-889. doi: 10.3324/haematol.2017.181628. Epub 2018 Mar 15.

2.

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Rodríguez-Otero P, Mateos MV, Martínez-López J, Martín-Calvo N, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Bargay J, Bengoechea E, González Y, de Oteyza JP, Gironella M, Encinas C, Martín J, Cabrera C, Palomera L, de Arriba F, Cedena MT, Paiva B, Puig N, Oriol A, Bladé J, Lahuerta JJ, San Miguel JF.

Leukemia. 2018 Feb 23. doi: 10.1038/s41375-018-0072-6. [Epub ahead of print]

PMID:
29515235
3.

Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study.

Jiménez C, Prieto-Conde MI, García-Álvarez M, Alcoceba M, Escalante F, Chillón MDC, García de Coca A, Balanzategui A, Cantalapiedra A, Aguilar C, Corral R, González-López T, Marín LA, Bárez A, Puig N, García-Mateo A, Gutiérrez NC, Sarasquete ME, González M, García-Sanz R.

Ann Hematol. 2018 Mar;97(3):475-484. doi: 10.1007/s00277-017-3207-3. Epub 2018 Jan 20.

PMID:
29353304
4.

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials.

Arana P, Paiva B, Cedena MT, Puig N, Cordon L, Vidriales MB, Gutierrez NC, Chiodi F, Burgos L, Anglada LL, Martinez-Lopez J, Hernandez MT, Teruel AI, Gironella M, Echeveste MA, Rosiñol L, Martinez R, Oriol A, De la Rubia J, Orfao A, Blade J, Lahuerta JJ, Mateos MV, San Miguel JF.

Leukemia. 2018 Apr;32(4):971-978. doi: 10.1038/leu.2017.320. Epub 2017 Nov 3.

PMID:
29099494
5.

The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma.

Hernández-García S, San-Segundo L, González-Méndez L, Corchete LA, Misiewicz-Krzeminska I, Martín-Sánchez M, López-Iglesias AA, Algarín EM, Mogollón P, Díaz-Tejedor A, Paíno T, Tunquist B, Mateos MV, Gutiérrez NC, Díaz-Rodriguez E, Garayoa M, Ocio EM.

Haematologica. 2017 Dec;102(12):2113-2124. doi: 10.3324/haematol.2017.168666. Epub 2017 Aug 31.

6.

From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.

Jiménez C, Alonso-Álvarez S, Alcoceba M, Ordóñez GR, García-Álvarez M, Prieto-Conde MI, Chillón MC, Balanzategui A, Corral R, Marín LA, Gutiérrez NC, Puig N, Sarasquete ME, González M, García-Sanz R.

Blood Cancer J. 2017 Aug 25;7(8):e591. doi: 10.1038/bcj.2017.72.

7.

Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma.

Rojas EA, Corchete LA, San-Segundo L, Martínez-Blanch JF, Codoñer FM, Paíno T, Puig N, García-Sanz R, Mateos MV, Ocio EM, Misiewicz-Krzeminska I, Gutiérrez NC.

Clin Cancer Res. 2017 Nov 1;23(21):6602-6615. doi: 10.1158/1078-0432.CCR-17-0678. Epub 2017 Aug 8.

PMID:
28790111
8.

Quantitative PCR: an alternative approach to detect common copy number alterations in multiple myeloma.

Chillón MC, Jiménez C, García-Sanz R, Alcoceba M, Prieto I, García-Alvarez M, Antón A, Maldonado R, Hernández-Ruano M, González M, Gutiérrez NC, Sarasquete ME.

Ann Hematol. 2017 Oct;96(10):1699-1705. doi: 10.1007/s00277-017-3083-x. Epub 2017 Aug 2.

PMID:
28770277
9.

Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

López-Iglesias AA, Herrero AB, Chesi M, San-Segundo L, González-Méndez L, Hernández-García S, Misiewicz-Krzeminska I, Quwaider D, Martín-Sánchez M, Primo D, Paíno T, Bergsagel PL, Mehrling T, González-Díaz M, San-Miguel JF, Mateos MV, Gutiérrez NC, Garayoa M, Ocio EM.

J Hematol Oncol. 2017 Jun 20;10(1):127. doi: 10.1186/s13045-017-0495-y.

10.

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival.

Herrero AB, Gutiérrez NC.

Front Oncol. 2017 May 19;7:98. doi: 10.3389/fonc.2017.00098. eCollection 2017.

11.

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, Martinez-Lopez J, Rosiñol L, Gutierrez NC, Martín-Ramos ML, Oriol A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De la Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF; GEM (Grupo Español de Mieloma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Group.

J Clin Oncol. 2017 Sep 1;35(25):2900-2910. doi: 10.1200/JCO.2016.69.2517. Epub 2017 May 12.

12.

DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.

Quwaider D, Corchete LA, Misiewicz-Krzeminska I, Sarasquete ME, Pérez JJ, Krzeminski P, Puig N, Mateos MV, García-Sanz R, Herrero AB, Gutiérrez NC.

J Hematol Oncol. 2017 Apr 18;10(1):92. doi: 10.1186/s13045-017-0461-8.

13.

Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma.

González-Calle V, Cerdá S, Labrador J, Sobejano E, González-Mena B, Aguilera C, Ocio EM, Vidriales MB, Puig N, Gutiérrez NC, García-Sanz R, Alonso JM, López R, Aguilar C, de Coca AG, Hernández R, Hernández JM, Escalante F, Mateos MV.

Haematologica. 2017 May;102(5):922-931. doi: 10.3324/haematol.2016.158345. Epub 2017 Jan 25.

14.

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.

Herrero AB, Rojas EA, Misiewicz-Krzeminska I, Krzeminski P, Gutiérrez NC.

Int J Mol Sci. 2016 Nov 30;17(12). pii: E2003. Review.

15.

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia.

Jovanovic JV, Chillón MC, Vincent-Fabert C, Dillon R, Voisset E, Gutiérrez NC, Sanz RG, Lopez AA, Morgan YG, Lok J, Solomon E, Duprez E, Díaz MG, Grimwade D.

Leukemia. 2017 Mar;31(3):747-751. doi: 10.1038/leu.2016.338. Epub 2016 Nov 22. No abstract available.

PMID:
27872498
16.

A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.

Jiménez C, Jara-Acevedo M, Corchete LA, Castillo D, Ordóñez GR, Sarasquete ME, Puig N, Martínez-López J, Prieto-Conde MI, García-Álvarez M, Chillón MC, Balanzategui A, Alcoceba M, Oriol A, Rosiñol L, Palomera L, Teruel AI, Lahuerta JJ, Bladé J, Mateos MV, Orfão A, San Miguel JF, González M, Gutiérrez NC, García-Sanz R.

J Mol Diagn. 2017 Jan;19(1):99-106. doi: 10.1016/j.jmoldx.2016.08.004. Epub 2016 Nov 15.

PMID:
27863261
17.

Origin of Waldenstrom's macroglobulinaemia.

García-Sanz R, Jiménez C, Puig N, Paiva B, Gutiérrez NC, Rodríguez-Otero P, Almeida J, San Miguel J, Orfão A, González M, Pérez-Andrés M.

Best Pract Res Clin Haematol. 2016 Jun;29(2):136-147. doi: 10.1016/j.beha.2016.08.024. Epub 2016 Oct 6. Review.

PMID:
27825459
18.

Integrative analysis of DNA copy number, DNA methylation and gene expression in multiple myeloma reveals alterations related to relapse.

Krzeminski P, Corchete LA, García JL, López-Corral L, Fermiñán E, García EM, Martín AA, Hernández-Rivas JM, García-Sanz R, San Miguel JF, Gutiérrez NC.

Oncotarget. 2016 Dec 6;7(49):80664-80679. doi: 10.18632/oncotarget.13025.

19.

Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone.

López-Iglesias AA, González-Méndez L, San-Segundo L, Herrero AB, Hernández-García S, Martín-Sánchez M, Gutiérrez NC, Paíno T, Avilés P, Mateos MV, San-Miguel JF, Garayoa M, Ocio EM.

Haematologica. 2017 Jan;102(1):168-175. doi: 10.3324/haematol.2016.146076. Epub 2016 Aug 18.

20.

Differentiation stage of myeloma plasma cells: biological and clinical significance.

Paiva B, Puig N, Cedena MT, de Jong BG, Ruiz Y, Rapado I, Martinez-Lopez J, Cordon L, Alignani D, Delgado JA, van Zelm MC, Van Dongen JJ, Pascual M, Agirre X, Prosper F, Martín-Subero JI, Vidriales MB, Gutierrez NC, Hernandez MT, Oriol A, Echeveste MA, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Morgan GJ, Orfao A, Blade J, Mateos MV, Lahuerta JJ, San-Miguel JF.

Leukemia. 2017 Feb;31(2):382-392. doi: 10.1038/leu.2016.211. Epub 2016 Aug 1.

21.

The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.

Paíno T, Garcia-Gomez A, González-Méndez L, San-Segundo L, Hernández-García S, López-Iglesias AA, Algarín EM, Martín-Sánchez M, Corbacho D, Ortiz-de-Solorzano C, Corchete LA, Gutiérrez NC, Maetos MV, Garayoa M, Ocio EM.

Clin Cancer Res. 2017 Jan 1;23(1):225-238. doi: 10.1158/1078-0432.CCR-16-0230. Epub 2016 Jul 20.

22.

Effects of IL-8 Up-Regulation on Cell Survival and Osteoclastogenesis in Multiple Myeloma.

Herrero AB, García-Gómez A, Garayoa M, Corchete LA, Hernández JM, San Miguel J, Gutierrez NC.

Am J Pathol. 2016 Aug;186(8):2171-2182. doi: 10.1016/j.ajpath.2016.04.003. Epub 2016 Jun 11.

PMID:
27301357
23.

Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

González-Calle V, Dávila J, Escalante F, de Coca AG, Aguilera C, López R, Bárez A, Alonso JM, Hernández R, Hernández JM, de la Fuente P, Puig N, Ocio EM, Gutiérrez NC, García-Sanz R, Mateos MV.

Leukemia. 2016 Oct;30(10):2026-2031. doi: 10.1038/leu.2016.123. Epub 2016 May 2.

PMID:
27133826
24.

Expression of MLL-AF4 or AF4-MLL fusions does not impact the efficiency of DNA damage repair.

Castaño J, Herrero AB, Bursen A, González F, Marschalek R, Gutiérrez NC, Menendez P.

Oncotarget. 2016 May 24;7(21):30440-52. doi: 10.18632/oncotarget.8938.

25.

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.

Paiva B, Cedena MT, Puig N, Arana P, Vidriales MB, Cordon L, Flores-Montero J, Gutierrez NC, Martín-Ramos ML, Martinez-Lopez J, Ocio EM, Hernandez MT, Teruel AI, Rosiñol L, Echeveste MA, Martinez R, Gironella M, Oriol A, Cabrera C, Martin J, Bargay J, Encinas C, Gonzalez Y, Van Dongen JJ, Orfao A, Bladé J, Mateos MV, Lahuerta JJ, San Miguel JF; Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups.

Blood. 2016 Jun 23;127(25):3165-74. doi: 10.1182/blood-2016-03-705319. Epub 2016 Apr 26.

26.

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis.

Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, Barrio S, Sanchez ML, Alignani D, Lasa M, García de Coca A, Pardal E, Oriol A, Garcia ME, Escalante F, González-López TJ, Palomera L, Alonso J, Prosper F, Orfao A, Vidriales MB, Mateos MV, Lahuerta JJ, Gutierrez NC, San Miguel JF.

Blood. 2016 Jun 16;127(24):3035-9. doi: 10.1182/blood-2015-10-673095. Epub 2016 Apr 11.

27.

In vivo adhesion of malignant B cells to bone marrow microvasculature is regulated by α4β1 cytoplasmic-binding proteins.

Martínez-Moreno M, Leiva M, Aguilera-Montilla N, Sevilla-Movilla S, Isern de Val S, Arellano-Sánchez N, Gutiérrez NC, Maldonado R, Martínez-López J, Buño I, García-Marco JA, Sánchez-Mateos P, Hidalgo A, García-Pardo A, Teixidó J.

Leukemia. 2016 Apr;30(4):861-72. doi: 10.1038/leu.2015.332. Epub 2015 Dec 10.

PMID:
26658839
28.

High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma.

Sebastián E, Alcoceba M, Martín-García D, Blanco Ó, Sanchez-Barba M, Balanzategui A, Marín L, Montes-Moreno S, González-Barca E, Pardal E, Jiménez C, García-Álvarez M, Clot G, Carracedo Á, Gutiérrez NC, Sarasquete ME, Chillón C, Corral R, Prieto-Conde MI, Caballero MD, Salaverria I, García-Sanz R, González M.

Ann Hematol. 2016 Jan;95(2):253-62. doi: 10.1007/s00277-015-2552-3. Epub 2015 Nov 14.

PMID:
26573278
29.

Effects of Different Surface Treatments on Composite Repairs.

Batista GR, Kamozaki MB, Gutierrez NC, Caneppele TM, Rocha Gomes Torres C.

J Adhes Dent. 2015 Aug;17(5):421-6. doi: 10.3290/j.jad.a35013.

PMID:
26525006
30.

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.

Mateos MV, Martínez-López J, Hernández MT, Ocio EM, Rosiñol L, Martínez R, Teruel AI, Gutiérrez NC, Martín Ramos ML, Oriol A, Bargay J, Bengoechea E, González Y, Pérez de Oteyza J, Gironella M, Encinas C, Martín J, Cabrera C, Paiva B, Cedena MT, Puig N, Bladé J, Lahuerta JJ, San-Miguel J.

Blood. 2016 Jan 28;127(4):420-5. doi: 10.1182/blood-2015-08-666537. Epub 2015 Oct 23.

31.

Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.

Misiewicz-Krzeminska I, Sarasquete ME, Vicente-Dueñas C, Krzeminski P, Wiktorska K, Corchete LA, Quwaider D, Rojas EA, Corral R, Martín AA, Escalante F, Bárez A, García JL, Sánchez-García I, García-Sanz R, San Miguel JF, Gutiérrez NC.

Clin Cancer Res. 2016 Jan 1;22(1):207-17. doi: 10.1158/1078-0432.CCR-14-2796. Epub 2015 Sep 4.

32.

Effect of Matrix Metalloproteinase-inhibiting Solutions and Aging Methods on Dentin Bond Strength.

Perote LC, Kamozaki MB, Gutierrez NC, Tay FR, Pucci CR.

J Adhes Dent. 2015 Aug;17(4):347-52. doi: 10.3290/j.jad.a34594.

PMID:
26295068
33.

The effect of CPP-ACP and Nd:YAG laser on the bond strength of softened dentin.

Kamozaki MB, Prakki A, Perote LC, Gutierrez NC, Pagani C.

Braz Oral Res. 2015;29. pii: S1806-83242015000100268. doi: 10.1590/1807-3107BOR-2015.vol29.0068. Epub 2015 Jun 16.

34.

Phase I/II study of weekly PM00104 (Zalypsis®) in patients with relapsed/refractory multiple myeloma.

Ocio EM, Oriol A, Bladé J, Teruel AI, Martín J, de la Rubia J, Gutiérrez NC, Rodríguez Díaz-Pavón J, Martínez González S, Coronado C, Fernández-García EM, Siguero Gómez M, Fernández-Teruel C, San Miguel J.

Br J Haematol. 2016 Feb;172(4):625-8. doi: 10.1111/bjh.13515. Epub 2015 Jun 2. No abstract available.

PMID:
26033438
35.

MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL.

Rodríguez-Vicente AE, Quwaider D, Benito R, Misiewicz-Krzeminska I, Hernández-Sánchez M, de Coca AG, Fisac R, Alonso JM, Zato C, de Paz JF, García JL, Sarasquete ME, Hernández JÁ, Corchado JM, González M, Gutiérrez NC, Hernández-Rivas JM.

BMC Cancer. 2015 Apr 8;15:238. doi: 10.1186/s12885-015-1212-2.

36.

Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability.

Herrero AB, San Miguel J, Gutierrez NC.

PLoS One. 2015 Mar 19;10(3):e0121581. doi: 10.1371/journal.pone.0121581. eCollection 2015.

37.

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

Paiva B, Corchete LA, Vidriales MB, García-Sanz R, Perez JJ, Aires-Mejia I, Sanchez ML, Barcena P, Alignani D, Jimenez C, Sarasquete ME, Mateos MV, Ocio EM, Puig N, Escalante F, Hernández J, Cuello R, García de Coca A, Sierra M, Montes MC, González-López TJ, Galende J, Bárez A, Alonso J, Pardal E, Orfao A, Gutierrez NC, San Miguel JF.

Blood. 2015 Apr 9;125(15):2370-80. doi: 10.1182/blood-2014-09-602565. Epub 2015 Feb 5.

38.

Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.

Agirre X, Castellano G, Pascual M, Heath S, Kulis M, Segura V, Bergmann A, Esteve A, Merkel A, Raineri E, Agueda L, Blanc J, Richardson D, Clarke L, Datta A, Russiñol N, Queirós AC, Beekman R, Rodríguez-Madoz JR, San José-Enériz E, Fang F, Gutiérrez NC, García-Verdugo JM, Robson MI, Schirmer EC, Guruceaga E, Martens JH, Gut M, Calasanz MJ, Flicek P, Siebert R, Campo E, Miguel JF, Melnick A, Stunnenberg HG, Gut IG, Prosper F, Martín-Subero JI.

Genome Res. 2015 Apr;25(4):478-87. doi: 10.1101/gr.180240.114. Epub 2015 Feb 2.

39.

The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution.

Puig N, Conde I, Jiménez C, Sarasquete ME, Balanzategui A, Alcoceba M, Quintero J, Chillón MC, Sebastián E, Corral R, Marín L, Gutiérrez NC, Mateos MV, González-Díaz M, San-Miguel JF, García-Sanz R.

Leukemia. 2015 Jun;29(6):1435-7. doi: 10.1038/leu.2015.7. Epub 2015 Jan 8. No abstract available.

PMID:
25567133
40.

Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma.

Krzeminski P, Sarasquete ME, Misiewicz-Krzeminska I, Corral R, Corchete LA, Martín AA, García-Sanz R, San Miguel JF, Gutiérrez NC.

Biochim Biophys Acta. 2015 Mar;1849(3):353-66. doi: 10.1016/j.bbagrm.2014.12.002. Epub 2014 Dec 11.

PMID:
25497370
41.

Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential.

Paíno T, Paiva B, Sayagués JM, Mota I, Carvalheiro T, Corchete LA, Aires-Mejía I, Pérez JJ, Sanchez ML, Barcena P, Ocio EM, San-Segundo L, Sarasquete ME, García-Sanz R, Vidriales MB, Oriol A, Hernández MT, Echeveste MA, Paiva A, Blade J, Lahuerta JJ, Orfao A, Mateos MV, Gutiérrez NC, San-Miguel JF.

Leukemia. 2015 May;29(5):1186-94. doi: 10.1038/leu.2014.321. Epub 2014 Nov 12.

PMID:
25388955
42.

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

Paiva B, Chandia M, Puig N, Vidriales MB, Perez JJ, Lopez-Corral L, Ocio EM, Garcia-Sanz R, Gutierrez NC, Jimenez-Ubieto A, Lahuerta JJ, Mateos MV, San Miguel JF.

Haematologica. 2015 Feb;100(2):e53-5. doi: 10.3324/haematol.2014.115162. Epub 2014 Nov 7. No abstract available.

43.

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.

Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T, García-Gómez A, Delgado M, Montero JC, Díaz-Rodríguez E, Mateos MV, Pandiella A, Couto S, Wang M, Bjorklund CC, San-Miguel JF.

Leukemia. 2015 Mar;29(3):705-14. doi: 10.1038/leu.2014.238. Epub 2014 Aug 8.

PMID:
25102946
44.

Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies.

López-Corral L, Corchete LA, Sarasquete ME, Mateos MV, García-Sanz R, Fermiñán E, Lahuerta JJ, Bladé J, Oriol A, Teruel AI, Martino ML, Hernández J, Hernández-Rivas JM, Burguillo FJ, San Miguel JF, Gutiérrez NC.

Haematologica. 2014 Aug;99(8):1365-72. doi: 10.3324/haematol.2013.087809. Epub 2014 May 9.

45.

A split-mouth randomized clinical trial of conventional and heavy flowable composites in class II restorations.

Rocha Gomes Torres C, Rêgo HM, Perote LC, Santos LF, Kamozaki MB, Gutierrez NC, Di Nicoló R, Borges AB.

J Dent. 2014 Jul;42(7):793-9. doi: 10.1016/j.jdent.2014.04.009. Epub 2014 Apr 25.

PMID:
24769385
46.

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.

Paíno T, Sarasquete ME, Paiva B, Krzeminski P, San-Segundo L, Corchete LA, Redondo A, Garayoa M, García-Sanz R, Gutiérrez NC, Ocio EM, San-Miguel JF.

PLoS One. 2014 Mar 21;9(3):e92378. doi: 10.1371/journal.pone.0092378. eCollection 2014.

47.

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.

Paiva B, Paino T, Sayagues JM, Garayoa M, San-Segundo L, Martín M, Mota I, Sanchez ML, Bárcena P, Aires-Mejia I, Corchete L, Jimenez C, Garcia-Sanz R, Gutierrez NC, Ocio EM, Mateos MV, Vidriales MB, Orfao A, San Miguel JF.

Blood. 2013 Nov 21;122(22):3591-8. doi: 10.1182/blood-2013-06-510453. Epub 2013 Sep 26.

48.

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma.

Sarasquete ME, Martínez-López J, Chillón MC, Alcoceba M, Corchete LA, Paiva B, Puig N, Sebastián E, Jiménez C, Mateos MV, Oriol A, Rosiñol L, Palomera L, Teruel AI, González Y, Lahuerta JJ, Bladé J, Gutiérrez NC, Fernández-Redondo E, González M, San Miguel JF, García-Sanz R.

Br J Haematol. 2013 Oct;163(2):223-34. doi: 10.1111/bjh.12519. Epub 2013 Aug 16.

PMID:
23952215
49.

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ.

Leukemia. 2014 Feb;28(2):384-390. doi: 10.1038/leu.2013.199. Epub 2013 Jul 2.

50.

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.

Paiva B, Vídriales MB, Rosiñol L, Martínez-López J, Mateos MV, Ocio EM, Montalbán MÁ, Cordón L, Gutiérrez NC, Corchete L, Oriol A, Terol MJ, Echeveste MA, De Paz R, De Arriba F, Palomera L, de la Rubia J, Díaz-Mediavilla J, Granell M, Gorosquieta A, Alegre A, Orfao A, Lahuerta JJ, Bladé J, San Miguel JF; Grupo Español de MM/Programa para el Estudio de la Terapéutica en Hemopatías Malignas Cooperative Study Group.

Leukemia. 2013 Oct;27(10):2056-61. doi: 10.1038/leu.2013.166. Epub 2013 Jun 7. Erratum in: Leukemia. 2013 Oct;27(10):2112.

PMID:
23743858

Supplemental Content

Loading ...
Support Center